New preprint on the efficacy of a single dose of the Oxford/AZ ChAdOx1 nCoV-19 vaccine. 76% efficacy against symptomatic infection from day 22 to day 90 post vaccination in 17,177 trial participants in UK, Brazil and South Africa:
papers.ssrn.com/sol3/papers.cf
Vaccine efficacy against symptomatic COVID-19 clearly higher with longer interval between first and second dose.
No-one in a population of 12,408 people vaccinated with a single dose of ChAdOx1 nCo-19 was hospitalised with COVID-19 from 22 days after immunisation.
mobile.twitter.com/ProfKatieEwer/status/1356627765060075521